Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan-Reference-Cited by-同舟云学术

Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan

Published:2021-11-13 Issue: Volume: Page:
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Treish Imad^ORCID,Al Rabayah Abeer^ORCID,Jaddoua Saad,Tuffaha Haitham^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-021-00293-4.pdf

Reference30 articles.

1. American Cancer Society. Global Cancer Facts & Figures 4th Edition. Published online 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf. Accessed 30 May 2021.

2. Glode AE, May MB. Rising cost of cancer pharmaceuticals: cost issues and interventions to control costs. Pharmacotherapy. 2017;37:85–93.

3. Savage P, Mahmoud S. Development and economic trends in cancer therapeutic drugs: a 5-year update 2010–2014. Br J Cancer. 2015;112:1037–41.

4. Nimri OF, Arqoub K. Statistical Digest Jordan Cancer Registry (JCR) Cancer Incidence in Jordan-2016 Non-Communicable Diseases Directorate-MOH. Publ Online. 2020. https://doi.org/10.13140/RG.2.2.31627.92961.

5. Jordan Statistical Yearbook 2017—Department of Statistics. http://dosweb.dos.gov.jo/products/statistical_yearbook2017/. Accessed 9 June 2021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Utility Analysis of Maintenance Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Non–Small Cell Lung Cancer in Jordan;Value in Health Regional Issues;2024-09

2. Cost-utility analysis of Pembrolizumab compared to other alternative immunotherapy and chemotherapy treatments for patients with advanced melanoma in Iran;Expert Review of Pharmacoeconomics & Outcomes Research;2023-09-27

3. Methodological Approaches to Cost-Effectiveness Analysis in Saudi Arabia: What Can We Learn? A Systematic Review;MDM Policy & Practice;2022-01